Aspirin cures erythromelalgia and cerebrovascular disturbances in JAK2-thrombocythemia through platelet-cycloxygenase inhibition

doi:10.5315/wjh.v6.i3.32

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 6, Issue 3

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (22952)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-19) series, Tables (1-4) series.

Item

Count

PDF

771

WORD

407

HTML

15684

Figures (1-19)

592

Tables (1-4)

411

Sum=17865

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

1034

Download

1654

Sum=2688

Publishing Process of This Article

Item

Count

Browse

1106

Download

1293

Sum=2399

Aug 6, 2017 (publication date) through Dec 18, 2024

Times Cited of This Article

Times Cited (4)

Journal Information of This Article

Publication Name

World Journal of Hematology

ISSN

2218-6204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Hematol. Aug 6, 2017; 6(3): 32-54
Published online Aug 6, 2017. doi: 10.5315/wjh.v6.i3.32

Full Size Figure Download Figure

Figure 8 Platelet survival curves in seven E+ thrombocythemia patients before and after aspirin 500 mg/day, and peripheral blood platelet counts before and after maintenance aspirin treatment 250 mg/d. MS: Mean survival; T1/2; MaLS: Maximal life span according to Branehög et al[50].

Citation: Michiels JJ. Aspirin cures erythromelalgia and cerebrovascular disturbances in JAK2-thrombocythemia through platelet-cycloxygenase inhibition. World J Hematol 2017; 6(3): 32-54
URL: https://www.wjgnet.com/2218-6204/full/v6/i3/32.htm
DOI: https://dx.doi.org/10.5315/wjh.v6.i3.32